Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force.

While grading the strength of recommendations and the quality of underlying evidence enhances the usefulness of clinical guidelines, the profusion of guideline grading systems undermines the value of the grading exercise. An American College of Chest Physicians (ACCP) task force formulated the criteria for a grading system to be utilized in all ACCP guidelines that included simplicity and transparency, explicitness of methodology, and consistency with current methodological approaches to the grading process. The working group examined currently available systems, and ultimately modified an approach formulated by the international GRADE group. The grading scheme classifies recommendations as strong (grade 1) or weak (grade 2), according to the balance among benefits, risks, burdens, and possibly cost, and the degree of confidence in estimates of benefits, risks, and burdens. The system classifies quality of evidence as high (grade A), moderate (grade B), or low (grade C) according to factors that include the study design, the consistency of the results, and the directness of the evidence. For all future ACCP guidelines, The College has adopted a simple, transparent approach to grading recommendations that is consistent with current developments in the field. The trend toward uniformity of approaches to grading will enhance the usefulness of practice guidelines for clinicians.

[1]  Douglas K Owens,et al.  Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. , 2006, Chest.

[2]  S. Pauker,et al.  Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[3]  G. Lip,et al.  Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[4]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[5]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[6]  A. Greinacher,et al.  Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[7]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[8]  Mohit Bhandari,et al.  Patients at the centre: in our practice, and in our use of language , 2004, ACP journal club.

[9]  D. Goldfarb Patients at the centre: in our practice, and in our use of language , 2004, ACP journal club.

[10]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.

[11]  G. Guyatt,et al.  A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  P. Jones,et al.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. , 2002, JAMA.

[13]  J. Cox,et al.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. , 2001, BMJ : British Medical Journal.

[14]  B. Chong,et al.  Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis , 2001, Thrombosis and Haemostasis.

[15]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[16]  H. Büller,et al.  Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. , 1999, Stroke.

[17]  G. Guyatt,et al.  Economic analysis of respiratory rehabilitation. , 1997, Chest.

[18]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[19]  Salim Yusuf,et al.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials , 1996, BMJ.

[20]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[21]  F Clerc,et al.  Long-term results of valve replacement with the St. Jude Medical prosthesis. , 1995, The Journal of thoracic and cardiovascular surgery.

[22]  G. Clagett,et al.  Antithrombotic therapy in peripheral arterial occlusive disease. , 1992, Chest.

[23]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.